Clinical Trial

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma. The primary hypotheses are that nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival.
Trial Details
NCT Number NCT06333821
Lead Sponsor Biotech Pharmaceutical Co., Ltd.
Conditions Cervical Cancer
Enrollment 460 participants
Start Date 2024-04-01
Primary Completion 2030-04-01 (estimated)
Study Completion 2030-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-03-27